Discover investment opportunities in Best Stocks To Buy Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $3 using our Smart AI Filter.
5 stocks found for "Best Stocks To Buy Under $3"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.19 | ±71.0% | -1.1 | 0.00% | |||
1.40 | ±59.3% | -45.5 | 0.00% | |||
0.44 | ±100.0% | -0.4 | 0.00% | |||
0.79 | ±46.9% | -62.2 | 0.00% | |||
1.19 | ±88.4% | -5.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read moreImmunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infections (COVID-19 and Influenza). The terms of the agreement were not disclosed.
Read moreQ: What are the characteristics of "XAIR" for potential investors?
A: "XAIR" operates in the medical device sector, focusing on innovative respiratory solutions. It may appeal to investors seeking growth opportunities in health tech. However, potential investors should analyze its financial health and competitive positioning before commitment.
Q: How does "DNN" fit within the context of energy investments?
A: "DNN" is involved in uranium mining, offering exposure to the nuclear energy sector. This may attract investors interested in clean energy transitions but wary of regulatory and market volatility associated with uranium.
Q: What drives "WRN" as a mining investment opportunity?
A: "WRN" focuses on mineral exploration, primarily copper and gold. Investors interested in commodities might value its potential for capitalizing on metal demand, though they should consider volatility and operational risks typical of the sector.
Q: Are there any income opportunities associated with the stock "RVPH"?
A: "RVPH" operates in the biopharmaceutical space. While currently focused on clinical development, its income potential might be limited at this stage. Investors typically view such companies for speculative growth rather than steady income.
Q: What sector-specific risks are associated with investing in "HURA"?
A: "HURA" provides investment exposure to uranium and nuclear energy. Sector-specific risks include regulatory changes, fluctuating uranium prices, and geopolitical factors influencing supply chains and energy policies.
Q: How can "IMUX"'s market presence affect its investment appeal?
A: "IMUX" is in the pharmaceuticals sector, focusing on immune modulation therapies. Its niche market and developmental pipeline may appeal to investors seeking innovation but are subject to clinical and regulatory risks.